SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging in conversation as a self-described Bitcoin parody that leans into its origins as an early 2011 internet joke to differentiate itself from newer meme coins. The community is actively debating its potential as a 'next-gen' asset, highlighting its long-standing lore and historical ties to the broader crypto ecosystem while dismissing recent unrelated copycats as scams.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is currently generating significant market conversation following a Canary Capital ETF filing that has renewed institutional interest and fueled community speculation about a potential major upward move. Investors are actively debating the token's long-term meme status versus its utility as a blue-chip asset, with many focusing on its price action as a key indicator of broader altcoin market health and potential rotation from Bitcoin.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is currently a focal point for investors as they anticipate a transformative FDA Biologics License Application (BLA) decision for their lead drug candidate, ivonescimab, which is being positioned as a potential disruptor in the lung cancer treatment landscape. The community is intensely focused on the company's clinical pipeline, with active discussions centering on the upcoming interim progression-free survival data and the broader competitive threat the drug poses to existing blockbuster immunotherapies.

Citigroup Global Markets Holdings, Inc. provides investment banking and securities brokerage services. It offers financial advisory, research and capital raising services to corporations, governments and individuals. The company was founded in 1977 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is currently drawing significant attention from investors as it hits fresh 52-week highs, driven by a combination of successful strategic divestitures in markets like Russia and Mexico and growing market optimism surrounding its long-term profitability overhaul. Traders are actively debating the sustainability of this recent rally, closely monitoring upcoming earnings as a potential catalyst while reacting to regulatory developments that are viewed as a positive signal for the bank's operational flexibility.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. The firm focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is capturing market attention as the bank navigates a complex environment of shifting private credit regulations and internal loan markdowns, while analysts closely monitor its role in major upcoming IPOs and the broader impact of AI-driven cyber threats on the financial sector. The community is actively debating the bank's defensive positioning and potential earnings strength, with traders specifically focused on its institutional options activity and price action relative to key sector support levels.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF (SMH) is trending as institutional investors debate whether the sector's aggressive AI-driven rally is facing a distribution phase or a continuation setup. The community is heavily focused on the disconnect between soaring AI infrastructure capex and mounting concerns over data center cancellations, power grid constraints, and valuation premiums.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is currently trending as investors weigh strong production performance and ongoing cost-synergy gains from the Marathon Oil acquisition against broader industry concerns over softening oil prices. The community is actively discussing the stock's resilience and dividend sustainability while monitoring how geopolitical tensions might influence future energy supply dynamics.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors digest news of its integration into BMW's upcoming vehicle line, sparking renewed focus on QNX's role as a foundational software layer for software-defined vehicles. Community sentiment remains polarized, with many retail holders maintaining long-term conviction in QNX's growth potential despite ongoing price volatility and frustrations over recent stock performance.

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Akoustis Technologies Inc

Akoustis Technologies has completed the sale of its assets to a subsidiary of SpaceX, formally concluding its Chapter 11 bankruptcy process. The community is actively discussing the impact of this liquidation, with many shareholders expressing that their equity positions have been wiped out following the finalization of the sale.

Lantheus Holdings, Inc. engages in the provision of diagnostic imaging and nuclear medicine products. The firm develops products that help healthcare professionals in patient management and outcomes and assists clinicians with the detection of cardiovascular disease. It operates through the U.S. and International geographical segments. The U.S. segment produces and markets products, radiopharmacies, PMFs, integrated delivery networks, hospitals, clinics, and group practices throughout the United States. The International segment offers direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America. The company was founded in 1956 and is headquartered in Bedford, MA.

Lantheus Holdings Inc

Lantheus Holdings is trending as investors monitor its ongoing strategic investment in Radiopharm Theranostics, fueling speculation about potential M&A activity given the company's aggressive expansion in the radiopharmaceutical space. The community is actively discussing the long-term growth potential of its diagnostic pipeline and closely analyzing management's ability to navigate increased competition in key imaging markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Issues Pessimistic Outlook for ENLV Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2026 earnings estimates for Enlivex Therapeutics in a research note issued to...

Research Analysts Set Expectations for ENLV Q1 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Free Report) - Investment analysts at HC Wainwright issued their Q1 2027 earnings estimates for shares of Enlivex Therapeutics in a report released on Tuesday, April 7th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.02) per share...

HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock

HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $13.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday...

Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Enlivex Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Enlivex Therapeutics Q4 Earnings Call Highlights

Enlivex Therapeutics (NASDAQ:ENLV) executives used the company's fourth-quarter and full-year 2025 earnings call to outline what they described as a dual-engine strategy that combines clinical-stage...

Enlivex Therapeutics (NASDAQ:ENLV) Releases Earnings Results, Beats Estimates By $12.88 EPS

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $12.85 earnings per share for the quarter, beating analysts' consensus...

<ul><li>Enlivex’s first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation model: A clinical-stage quality longevity program powered by a prediction markets treasury strategy.</li><li>IND clearance follows the positive 3 and 6-month data readout from the Company’s Phase 1/2a multicenter, randomized, double-blind, placebo-controlled clinical trial, which enrolled 134 patients, and demonstrated a robust, durable, clinically meaningful, and statistically significant treatment effect in older patients with knee osteoarthritis.</li></ul>Nes-Ziona, Israel, March 23, 2026 (GLOBE NEWSWIRE) — Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Allocetra™, the Company’s clinical-stage immunotherapy, for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA).The FDA’s clearance enables Enlivex to initiate a global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis, which is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040.This is the first regulatory clearance obtained by the Company following the implementation of its dual-engine value creation model, which is centered on the development of a clinical-stage quality longevity program powered by a prediction markets treasury strategy.Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, “We are very pleased to have received FDA clearance to initiate the Phase 2b clinical trial of Allocetra™ in patients with age-related primary knee osteoarthritis. This milestone represents an important step toward our mission of improving the quality of life of an aging population that is suffering from this debilitating disease with poor availability of treatment options. In our previous clinical study, Allocetra™ demonstrated a robust, durable, and clinically meaningful treatment effect lasting at least six months, with increasing benefit observed in older patient populations. We look forward to enrolling the first patients into the Phase 2b and believe Allocetra™ has the potential to address a major unmet medical need for elderly patients suffering from knee osteoarthritis while supporting a strong commercial opportunity for Enlivex.”The Phase 2b trial has been designed to be statistically powered to evaluate key efficacy endpoints, including change from baseline in pain and physical function compared with placebo, measured at three- and six-months following treatment. Additional endpoints include changes in quality-of-life measures and functional mobility assessments.About Enlivex (Nasdaq: ENLV)Enlivex is a quality longevity Company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging with a primary focus on age-related osteoarthritis.In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the RAIN protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual-engine structure combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.About Knee OsteoarthritisKnee osteoarthritis (KOA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to impact 78 million Americans by 2040. There are currently no approved disease modifying therapies; treatment is largely limited to pain relief, intra articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of knee OA patients are 60 years and older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” and other words of similar meaning, including statements relating to the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company’s ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company’s operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.ENLIVEX CONTACTShachar Shlosberger, CFO Enlivex Ltd. <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=9Rln_Ms_YDeRPyQEv-oocAqcVW9S1vSSlmOHeWY4dao7nXzR7IbvSuoGEwQTnQ1n1EBwJxQAMhb9vYDbQfZKdZpuk5FsnmAIYb__INu_oD4=">shachar@enlivex.com</a>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis

FDA clears Enlivex’s Phase 2b trial for Allocetra™ to treat age-related knee osteoarthritis.

Others

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday

Enlivex Therapeutics (NASDAQ:ENLV) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-enlivex-therapeutics-ltd-stock...

Enlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Hold at Wall Street Zen

Wall Street Zen raised shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Wednesday

Enlivex Therapeutics (NASDAQ:ENLV) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

Enlivex Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

Current Price	$0.9615
Prev Close	$0.9496
Open	$0.9313
Dividend Yield	0.00%
50-Day Moving Average	$1.07
Beta	0.74
Avg. Volume	792,658.31
PE Ratio	0.04

52-Week High	$2.10
52-Week Low	$0.66
Market Capitalization	$228.24M
EPS (Annual)	$25.48
Price to Book	0.12
Revenue Per Employee	$0.00

ENLV
Enlivex Therapeutics Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest ENLV News

ENLVEnlivex Therapeutics Ltd